Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 94 of 114, showing 5 Applications out of 567 total, starting on record 466, ending on 470

# Protocol No Study Title Investigator(s) & Site(s)

466.

ECCT/10/03/03   High-Dose Fluconazole Treatment in AIDS-Associated CM
    A5225/HiFLAC: A Phase I/II Dose-Finding Study of High-Dose Fluconazole Treatment in AIDS-Associated Cryptococcal Meningitis   
Principal Investigator(s)
1. Abraham Mosigisi Siika
Site(s) in Kenya
1. Moi University Clinical Research Centre (Uasin Gishu county)
 
View

467.

ECCT/19/04/03   Phase III pediatric study with the L-PZQ ODTs
    An Open-label, Phase 3 efficacy and safety study of L-praziquantel orodispersible tablets (L-PZQ ODT) in Schistosoma-infected children 3 months to 6 years of age, including a 2:1 randomized, controlled cohort of Schistosoma mansoni-infected children 4 to 6 years of age treated with L-PZQ ODT or commercial PZQ (Biltricide®)   
Principal Investigator(s)
1. Maurice Reuben Odiere
Site(s) in Kenya
KEMRI-Centre for Global Health Research (CGHR)
 
View

468.

ECCT/25/04/07   Server migration
    Server Migration   
Principal Investigator(s)
1. Server Migration Server Migration
Site(s) in Kenya
Server Migration
 
View

469.

ECCT/20/03/01   GlycoShig3
    A Phase 2a age descending study to investigate the safety and immunogenicity of the SF2a-TT15 synthetic carbohydrate-based conjugate vaccine against Shigella flexneri 2a in adult, children and infant target population in endemic countries.   
Principal Investigator(s)
1. Fredrick Kipyegon Sawe
Site(s) in Kenya
Kenya Medical Research Institute Walter Reed Project Kericho
 
View

470.

ECCT/22/03/04   VIBRI COVID-19-001/2021
    A Multi-Centre, Randomized, Double Blind, Phase 2b Trial to Evaluate the Safety and Immunogenicity of Janssen Ad26COVS1 and Novavax NVX-CoV2373 COVID-19 vaccines for Homologous and Heterologous Boosting in Adolescents and Adults Aged 12 to 64 Years with and without HIV infection in 3 African Countries (Kenya, Democratic Republic of Congo, and Rwanda).   
Principal Investigator(s)
1. Dr. Lucas Otieno Tina
Site(s) in Kenya
Victoria Biomedical Research Institute,
 
View